Varegacestat - Immunome
Alternative Names: AL-102; BMS 986115; WHG-626Latest Information Update: 25 Nov 2024
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Developer Ayala Pharmaceuticals; Bristol-Myers Squibb; Novartis
- Class Amides; Antineoplastics; Benzene derivatives; Benzodiazepines; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Fibroma
- No development reported Haematological malignancies; Multiple myeloma; Solid tumours
Most Recent Events
- 11 Nov 2024 Immunome initiates enrolment in a phase-I trial (In volunteers) in USA (Unspecified), (NCT06677996)
- 07 Nov 2024 Immunome plans to initiate a phase I trial in healthy volunteers in the US (NCT06677996)
- 28 May 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Unknown (PO)